Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Novartis has partnered with a consortium of life sciences companies to rapidly develop, produce and deliver vaccines, diagnostics and treatments for Covid-19 coronavirus infection.

The partners will combine their assets, resources and expertise, working with the Bill & Melinda Gates Foundation, to accelerate the fight against the pandemic.

Novartis CEO Vas Narasimhan serves as a co-chair of a consortium of life science companies with headquarters in three continents.

Narasimhan said: “In addition to the individual contributions companies are already making, collective action is critical to ensure any promising studies into vaccines, drugs, and diagnostics are quickly scaled to people around the world who are affected by this pandemic.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As well as Novartis, companies participating in the alliance involve Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline (GSK), Bristol-Myers Squibb, Merck (MSD), Pfizer, Eisai, Johnson & Johnson, Sanofi, Merck KGaA, BD and bioMérieux.

After a recent conference call with Gates Foundation, 15 companies agreed to share their molecular compound libraries with some existing safety and activity data.

The libraries will be shared alongside the Covid-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome and Mastercard earlier this month for screening for potential against the new viral infection.